GSK's $10.6 Billion Acquisition of Nuvalent Signals a Bold Step in Cancer Treatment
GSK's acquisition of Nuvalent for $10.6 billion represents a significant investment in the biopharma sector, particularly in targeted cancer therapies.
Editorial Staff 8 days ago